New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:13 EDTACT, ATRSAntares Pharma reports Q4 EPS (4c), consensus (5c)
Antares Pharma (ATRS) reports Q4 revenue $4.75M, consensus $6.15M. The company said "Product revenue decreased in Q4 to $0.9M. The decrease in product revenues in Q4 was primarily due to a decrease in sales of oxybutynin gel 3% product to Actavis (ACT), as Actavis assumed all manufacturing of Gelnique 3% in 1Q13, as contracted.
News For ATRS;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
16:21 EDTATRSAntares Pharma gets written notice of termination of agreement from Pfizer
On December 12, 2011, Antares Pharma (ATRS) entered into a licensing agreement with Pfizer (PFE) Consumer Healthcare for one of our drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. On October 5, the Company received a written notice of termination of the Agreement from Pfizer. Pfizer informed the Company that the product Pfizer was developing failed to meet pre-specified endpoints in a clinical study. Accordingly, the Agreement will terminate on November 5.
September 28, 2015
07:12 EDTATRSAntares announces publication of QuickShot Testosterone data in health journal
Subscribe for More Information
September 25, 2015
08:37 EDTATRSAntares Pharma could benefit from drug pricing controversy, says Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use